Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines
暂无分享,去创建一个
Ferdousi Chowdhury | C. Ottensmeier | A. Mander | F. Chowdhury | Ann Mander | Lindsey Low | Christian H. Ottensmeier | L. Low
[1] R. Young,et al. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.
[2] D. Ankerst,et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT , 2005, BMC Immunology.
[3] Holden T Maecker,et al. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides , 2008, BMC Immunology.
[4] S. H. van der Burg,et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.
[5] J. Schlom,et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.
[6] F. Stevenson,et al. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. , 2006, Blood.
[7] M. Caulfield,et al. Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions , 2007, Clinical and Vaccine Immunology.
[8] A. Iasonos,et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission , 2008, Clinical Cancer Research.
[9] P. Coulie,et al. T-cell responses of vaccinated cancer patients. , 2003, Current opinion in immunology.
[10] Xu Liu,et al. Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus , 2001, Clinical Diagnostic Laboratory Immunology.
[11] M. Carroll,et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses , 2008, Cancer Immunology, Immunotherapy.
[12] A. Ribas,et al. Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma , 2008, Journal of immunotherapy.
[13] F. Marincola,et al. Natural T cell immunity against cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] Krys J. Miller,et al. Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.
[15] B. Ludewig,et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma , 2006, Cancer Immunology, Immunotherapy.
[16] C. Gouttefangeas,et al. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? , 2007, Cancer Immunology, Immunotherapy.
[17] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[18] P. Moss,et al. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. , 2006, Cancer research.
[19] H. Sampson,et al. Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study , 2006, BMC Immunology.
[20] M. Atkins,et al. Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy , 2002, Journal of immunotherapy.
[21] E. Thiel,et al. Differences in T‐cell immunity toward tumor‐associated antigens in colorectal cancer and breast cancer patients , 2003, International journal of cancer.
[22] J. Lathey. Preliminary steps toward validating a clinical bioassay: A case study of the ELIspot assay , 2003 .
[23] A. Eggermont,et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.
[24] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.
[25] Sylvia Janetzki,et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.
[26] Herman Pieterse,et al. Richtsnoer voor Good Clinical Practice (CPMP/ICH/135/95). , 2004 .
[27] E. Celis,et al. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. , 2002, Cancer research.
[28] B. Boehm,et al. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. , 2003, Journal of immunological methods.
[29] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[30] Sylvia Janetzki,et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.
[31] A. Mackensen,et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.
[32] D. Voehringer,et al. Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1) , 2003, Experimental Gerontology.
[33] Ashley M. Miller,et al. Immune Monitoring in a Phase 1 Trial of a PSA DNA Vaccine in Patients with Hormone-Refractory Prostate Cancer , 2005, Journal of immunotherapy.
[34] M. Baseler,et al. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets , 2004, Journal of Translational Medicine.
[35] C. Herberts,et al. A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.
[36] C. Ottensmeier,et al. DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.
[37] J Cummings,et al. Biomarker method validation in anticancer drug development , 2008, British journal of pharmacology.